Shilajit — a resinous mineral pitch harvested from high-altitude rock faces across the Himalayas, Altai, and Caucasus ranges — has been used in Ayurvedic and traditional medicine for centuries under the premise that it supports vitality and whole-body health. Its best-studied bioactive constituents, fulvic acid, humic acids, and dibenzo-alpha-pyrones (DBPs), have drawn researchers into asking whether shilajit might exert meaningful effects on cardiovascular function and metabolic health.
Interest in shilajit and heart health has grown partly because its proposed actions — supporting mitochondrial energy production, modulating inflammatory pathways, and influencing metabolic processes — overlap with mechanisms that are relevant to cardiovascular disease. The honest starting point, however, is that most of this research is at an early stage, conducted primarily in animals or very simple model organisms. Human data do exist, but they are thin and pull in different directions: one small uncontrolled study reported improved blood lipids, a controlled study that measured a lipid panel found no change, and the one recent randomized cardiometabolic trial gave shilajit only as a minor component of a three-ingredient formula. No adequately powered trial has tested shilajit on its own against placebo for cholesterol or cardiac outcomes, and that gap matters when making decisions about supplementation.
Key Takeaways
- Animal research suggests shilajit may reduce cardiac injury markers in induced myocardial damage models [1], but no human trial has tested shilajit on its own for a cardiac outcome.
- Human lipid data are mixed and weak: a small 2003 uncontrolled study in healthy volunteers reported lower total cholesterol and triglycerides with higher HDL [2], while a controlled 2016 study that measured a lipid panel found no change [3].
- Hepatoprotective effects observed in high-fat diet rat models [4] suggest indirect metabolic relevance to cardiovascular risk, but cannot be extrapolated to cholesterol management in people.
- A human skeletal muscle study found shilajit upregulated 17 extracellular-matrix genes [3], a tissue-remodeling signal rather than a mitochondrial one, so it does not support the energy-metabolism claim often made for shilajit.
- Heavy metal contamination risk is real; only third-party-tested purified products should be used, and anyone with heart disease or on cardiac medications should consult a doctor before starting shilajit.
What Is Shilajit and Why Might It Affect the Heart?
Shilajit is not a single molecule but a complex mixture formed over centuries by the microbial decomposition of plant matter compressed between mountain rocks. Its primary bioactive constituents include fulvic acid, humic acids, and dibenzo-alpha-pyrones. Fulvic acid in particular is thought to improve mineral transport across cell membranes and to participate as an electron carrier in cellular energy metabolism — a property theoretically relevant to heart muscle, which has extraordinarily high continuous energy demands.
The proposed cardiovascular mechanisms include improved mitochondrial efficiency (heart cells depend heavily on mitochondrial ATP production), anti-inflammatory activity from humic acids, and antioxidant effects that could reduce oxidative stress on arterial walls. These are plausible biological pathways, but a plausible mechanism does not equal proven clinical benefit. That requires controlled human trials, which remain limited or absent for the cardiovascular and cholesterol questions most consumers ask about.
Animal Evidence for Cardioprotective Effects
The most directly relevant study in the available evidence comes from a 2014 experiment examining shilajit in a model of induced cardiac injury. Researchers administered mumie — the Russian and Central Asian name for shilajit — to animals with experimentally induced myocardial injury and measured markers of cardiac damage. The treated animals showed reduced signs of myocardial injury compared to controls, suggesting a cardioprotective effect [1].
This finding is encouraging at a preclinical level but must be interpreted carefully. Experimental myocardial injury in rodents is a controlled acute-damage model; it does not map cleanly onto chronic cardiovascular disease, atherosclerosis, or the kind of lipid-driven arterial narrowing most people associate with heart risk. Results from such models frequently fail to translate to human clinical outcomes, and no published trial has tested shilajit on its own for a cardiac outcome in people. The closest human evidence is a 2025 randomized, double-blind, placebo-controlled trial that measured vascular endpoints including pulse wave velocity and flow-mediated dilation [5], but shilajit appeared there only as 6 to 12 mg inside a chromium and Phyllanthus emblica formula, so nothing in it can be attributed to shilajit alone.
A separate, explicitly preliminary study examined shilajit’s effect on the heart of Daphnia — microscopic crustaceans sometimes used as simple cardiac models because their transparent bodies allow direct observation of heartbeats [6]. The study documented changes in Daphnia heart rate following shilajit exposure. The authors themselves described this work as preliminary, and observations in such a simple organism should not be extrapolated to human cardiac physiology.
Shilajit, Liver Health, and Metabolic Cardiovascular Risk
Cardiovascular risk is tightly linked to metabolic health. Non-alcoholic fatty liver disease (NAFLD) in particular is associated with dyslipidemia, elevated triglycerides, and insulin resistance — all recognized contributors to heart disease. A 2020 animal study found that shilajit demonstrated hepatoprotective effects in rats fed a high-fat diet designed to induce NAFLD, with treated animals showing improved liver parameters compared to controls [4].
This is relevant to the cardiovascular conversation because if shilajit supports liver function under conditions of high metabolic stress in animal models, it raises a hypothesis — not yet a proven clinical fact — that it might modestly influence metabolic cardiovascular risk markers. Connecting liver health to cholesterol regulation is mechanistically sound, since the liver is central to lipoprotein synthesis and clearance. However, animal NAFLD models and human cholesterol management are meaningfully different, and this connection requires dedicated human research to evaluate.
Shilajit and Cholesterol: An Honest Assessment
Despite frequent marketing claims linking shilajit to cholesterol reduction, the human lipid evidence is small, old, and contradictory. A 2003 study gave 2 g of shilajit daily for 45 days to healthy volunteers and reported significant reductions in serum cholesterol and triglycerides alongside higher HDL [2]. That study had no placebo arm, was published in a small journal, and has not been replicated. Pulling the other way, the 2016 controlled human study of 250 mg twice daily also measured a lipid panel and found no change after 8 weeks, nor after a further 4 weeks combined with exercise [3]. A 2025 randomized placebo-controlled trial did include blood lipids among its endpoints [5], but tested shilajit only as a minor part of a combination product. Anyone buying shilajit specifically for lipid management should understand they would be acting on one unreplicated, uncontrolled study, against a controlled study that found nothing.
Beyond those human studies, the indirect connections to lipid metabolism come from the metabolic liver research in rats [4] and from the broader theoretical framework in which shilajit’s anti-inflammatory and mitochondrial-support properties are proposed to operate. These are preliminary leads, not established findings. Anyone with clinically elevated cholesterol or established cardiovascular disease should work with a physician using interventions that carry robust, replicated human evidence.
Energy Metabolism and the Heart: The Mitochondrial Connection
The heart is one of the most metabolically demanding organs in the body, requiring a continuous large supply of ATP to sustain contractile function. A 2016 human study examined oral shilajit supplementation’s effects on gene expression in skeletal muscle [3]. It is worth being precise about what that study found, because it is often described incorrectly: the significantly upregulated cluster was 17 extracellular-matrix genes, including tenascin XB, decorin, myoferlin, collagen, elastin, fibrillin 1, and fibronectin 1. Those are structural and tissue-repair genes. The study did not report a mitochondrial gene signature, so it cannot be used as human evidence for a mitochondrial mechanism.
Cardiac mitochondrial dysfunction plays a role in conditions like heart failure, where the heart’s energy production becomes impaired. The hypothesis that shilajit’s fulvic acid and DBPs support mitochondrial electron transport chains comes from laboratory and animal work, not from human tissue: the human transcriptome data [3] point to extracellular-matrix remodeling instead. Whether the mitochondrial hypothesis translates to measurable cardiac benefit in healthy people or those at cardiovascular risk has not been tested in a clinical trial.
Safety Considerations: Heavy Metals, Drug Interactions, and Who Should Be Careful
A critical concern with shilajit — particularly relevant to cardiovascular health — is heavy metal contamination. Raw or poorly processed shilajit can contain elevated levels of lead, arsenic, or mercury. Heavy metal toxicity carries its own cardiovascular risks: lead exposure is associated with elevated blood pressure and increased cardiac event risk. This makes product purity non-negotiable; only third-party-tested, purified shilajit should be considered.
Shilajit has also demonstrated parasympathomimetic activity in animal tissue studies [7], meaning it may influence the autonomic nervous system in ways that could theoretically affect heart rate or blood pressure. Whether this effect is clinically significant in humans at typical supplemental doses is not established, but it is a reason for caution in people taking antihypertensives, antiarrhythmics, beta-blockers, or anticoagulants. Pregnant or breastfeeding individuals, those with kidney disease, and anyone with pre-existing heart conditions should consult a physician before using shilajit.
🛒 Where to Buy Shilajit
- Pürblack Live ResinLab-tested / studied
resin, ~300-500 mg/day — Premium purified resin, third-party heavy-metal tested; widely regarded as a reference-quality resin. - Toniiq Shilajit
capsules, 500 mg — Standardized fulvic-acid %, third-party tested generic. - Nutricost Shilajit Extract
capsules, 500 mg — Low-cost large-count bottles. - Double Wood Shilajit
capsules, 500 mg — Budget-friendly, COA on request.
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
Most shilajit cardiovascular research has been conducted in animals or highly simplified model organisms. The few human studies that measured blood lipids disagree with each other, and the one randomized cardiometabolic trial tested shilajit only inside a combination product, so no large trial confirms a cardiovascular effect of shilajit itself in people. Unprocessed or low-quality shilajit may contain harmful levels of heavy metals — always choose a product with verified third-party purity testing, and consult a qualified healthcare provider before use, particularly if you have heart disease, take prescription medications, or are pregnant or breastfeeding. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
Does shilajit lower cholesterol?
The human evidence is mixed and too weak to rely on. A small 2003 study in healthy volunteers taking 2 g daily for 45 days reported lower total cholesterol and triglycerides with higher HDL [2], but it had no placebo group and has not been replicated. A controlled 2016 study that measured a lipid panel found no change [3]. No adequately powered trial has tested shilajit alone against placebo for cholesterol. Anyone with high cholesterol should pursue evidence-based interventions under medical supervision.
Is shilajit good for the heart?
A 2014 animal study found that shilajit (mumie) exerted cardioprotective effects in a model of experimentally induced myocardial injury [1], and a preliminary study observed heart-rate effects in Daphnia [6]. These are early, non-human findings. No published trial has tested shilajit on its own for a cardiac outcome in people, and the one randomized trial carrying vascular endpoints gave shilajit only as 6 to 12 mg inside a three-ingredient formula [5].
How does shilajit affect energy metabolism, and does that relate to heart health?
A 2016 human study found that oral shilajit supplementation altered gene expression in skeletal muscle, but the genes it upregulated were 17 extracellular-matrix transcripts such as collagen, elastin and decorin, not mitochondrial ones [3]. The mitochondrial energy-metabolism idea remains a laboratory hypothesis rather than a human finding, and direct cardiac-tissue or heart-outcome data in humans are not available.
Can shilajit affect heart rate or blood pressure?
Animal studies have shown shilajit can produce parasympathomimetic effects — mimicking the parasympathetic nervous system, which generally slows heart rate [7]. A Daphnia model study also found shilajit influenced heart rate in that organism [6]. Human data on these effects are absent. People on medications affecting heart rate or blood pressure should consult a physician before using shilajit.
Is shilajit safe for people with cardiovascular disease?
There is insufficient human clinical evidence to make a safety or efficacy claim for shilajit in people with existing cardiovascular disease. Additionally, low-quality or raw shilajit can contain heavy metals such as lead, which are themselves cardiovascular risk factors. Anyone with heart disease, hypertension, or who takes prescription cardiac medications should seek physician guidance before using any shilajit product.
How does shilajit's proposed mechanism differ from standard heart supplements?
Unlike vitamin-based antioxidants, shilajit’s fulvic acid and dibenzo-alpha-pyrones are proposed to directly participate in mitochondrial electron transport — functioning as energy-metabolism modulators rather than passive free-radical scavengers. Human skeletal muscle research does not support that mechanism directly: the genes it found upregulated were extracellular-matrix rather than mitochondrial [3]. Whether the proposed mitochondrial route confers a meaningful cardiovascular advantage over established lifestyle and dietary interventions has not been tested in clinical trials.
References
- Joukar S et al. Cardioprotective effect of mumie (shilajit) on experimentally induced myocardial injury. Cardiovascular toxicology (2014). PMID 24448712
- Sharma P et al. Shilajit: evaluation of its effects on blood chemistry of normal human subjects. Ancient science of life (2003). PMID 22557121
- Das A et al. The Human Skeletal Muscle Transcriptome in Response to Oral Shilajit Supplementation. Journal of medicinal food (2016). PMID 27414521
- Ghezelbash B et al. Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats. Hormone molecular biology and clinical investigation (2020). PMID 32083445
- Martinez V et al. Effects of 12 Weeks of Chromium, Phyllanthus emblica Fruit Extract, and Shilajit Supplementation on Markers of Cardiometabolic Health, Fitness, and Weight Loss in Men and Women with Risk Factors to Metabolic Syndrome: A Randomized Double-Blind, Placebo-Controlled Trial. Nutrients (2025). PMID 40573153
- Gaikwad NS et al. Effect of shilajit on the heart of Daphnia: A preliminary study. Journal of Ayurveda and integrative medicine (2012). PMID 22529672
- Kaur S et al. Parasympathomimetic effect of shilajit accounts for relaxation of rat corpus cavernosum. American journal of men's health (2013). PMID 23060465
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
